ADC Therapeutics SA Proxy Materials Filed
Ticker: ADCT · Form: DEFA14A · Filed: Apr 21, 2025 · CIK: 1771910
| Field | Detail |
|---|---|
| Company | Adc Therapeutics SA (ADCT) |
| Form Type | DEFA14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-voting, corporate-governance
TL;DR
ADC Therapeutics proxy materials are in! Vote online, go paperless.
AI Summary
ADC Therapeutics SA filed a Definitive Additional Materials proxy statement on April 21, 2025. The filing relates to the company's proxy materials and provides information for shareholders regarding upcoming decisions. Shareholders can access proxy materials and vote online, with an option to consent to electronic delivery of future documents.
Why It Matters
This filing provides shareholders with essential information to participate in corporate governance by voting on important company matters. It also outlines options for electronic delivery of future shareholder communications.
Risk Assessment
Risk Level: low — This is a routine proxy filing providing information to shareholders and does not indicate any immediate financial or operational risks.
Key Players & Entities
- ADC Therapeutics SA (company) — Registrant
- 0000950103-25-005077.txt (document) — Filing document identifier
- 20250421 (date) — Filing date
FAQ
What type of filing is this DEFA14A for ADC Therapeutics SA?
This filing is a Definitive Additional Materials proxy statement, filed on April 21, 2025.
Where can shareholders view proxy materials and vote?
Shareholders can access proxy materials and vote online, as indicated in the filing.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the business address of ADC Therapeutics SA?
The business address is Biopole, Route de la Corniche 3B, Epalinges, 1066.
What is the SIC code for ADC Therapeutics SA?
The Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 21, 2025 regarding ADC Therapeutics SA (ADCT).